Shinpoong Pharmaceutical Overview
- Year Founded
-
1962
- Status
-
Public
- Employees
-
822
- Stock Symbol
-
019170
- Investments
-
5
- Share Price
-
$5.94
- (As of Friday Closing)
Shinpoong Pharmaceutical General Information
Description
Shinpoong Pharmaceutical Co Ltd specializes in manufacturing remedy drugs and also active pharmaceutical ingredients and finished products. Its products include Newsicam, Caravenal, Roxagen, Clamoxin duo, Ceroxim, and Clocin. The firm's production facilities are located at Gyeonggi-do and Cheongwon-gun.
Contact Information
Website
www.shinpoong.co.krCorporate Office
- 161, Yeoksam-ro
- Gangnam-gu
- Seoul, Gangnam 06246
- South Korea
Corporate Office
- 161, Yeoksam-ro
- Gangnam-gu
- Seoul, Gangnam 06246
- South Korea
Shinpoong Pharmaceutical Stock Performance
As of 13-Nov-2026, Shinpoong Pharmaceutical’s stock price is $5.94. Its current market cap is $326M with 53.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.94 | $6.01 | $4.37 - $10.66 | $326M | 53.7M | 517K |
Shinpoong Pharmaceutical Financials Summary
As of 30-Jun-2026, Shinpoong Pharmaceutical has a trailing 12-month revenue of $165M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 286,870 | 507,686 | 354,191 | 524,470 |
| Revenue | 164,730 | 164,904 | 162,041 | 153,144 |
| EBITDA | 9,190 | 15,294 | (536) | (31,350) |
| Net Income | (562) | 6,201 | (11,277) | (43,845) |
| Total Assets | 237,525 | 244,767 | 232,247 | 271,661 |
| Total Debt | 34,531 | 38,789 | 37,066 | 35,813 |
Shinpoong Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Shinpoong Pharmaceutical Patents
Shinpoong Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026167528-A1 | Composition comprising quinazoline-2,4-dione derivative | Pending | 04-Feb-2025 | ||
| WO-2026167529-A1 | Composition comprising quinazoline-2,4-dione derivative | Pending | 04-Feb-2025 | ||
| WO-2026167530-A1 | Composition for prevention or treatment of ischemic stroke | Pending | 04-Feb-2025 | ||
| WO-2026168919-A1 | Novel crystal form of quinazoline -2,4-dione compound and method for preparing same | Pending | 04-Feb-2025 | ||
| WO-2026117086-A1 | Composition for treating joint diseases and preparation method therefor | Pending | 29-Nov-2024 | A61K31/728 |
Shinpoong Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Shinpoong Pharmaceutical Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Shinpoong Pharmaceutical Investments (5)
Shinpoong Pharmaceutical’s most recent deal was a Later Stage VC with Nextgen Bioscience. The deal was made on 11-Jul-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Nextgen Bioscience | 11-Jul-2023 | Later Stage VC | Drug Discovery | ||
| C-BIOMEX | 21-Jun-2022 | Later Stage VC | Biotechnology | ||
| Biobab AiBIO | 15-Mar-2021 | Early Stage VC | Drug Discovery | ||
| C-BIOMEX | 01-Dec-2018 | Seed Round | Biotechnology | ||
| C-BIOMEX | 20-Dec-2017 | Seed Round | Biotechnology |
Shinpoong Pharmaceutical ESG
Risk Overview
Risk Rating
Updated September, 30, 2025
40.88 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Pharmaceuticals
Subindustry
of 406
Rank
Percentile
Shinpoong Pharmaceutical FAQs
-
When was Shinpoong Pharmaceutical founded?
Shinpoong Pharmaceutical was founded in 1962.
-
Where is Shinpoong Pharmaceutical headquartered?
Shinpoong Pharmaceutical is headquartered in Seoul, South Korea.
-
What is the size of Shinpoong Pharmaceutical?
Shinpoong Pharmaceutical has 822 total employees.
-
What industry is Shinpoong Pharmaceutical in?
Shinpoong Pharmaceutical’s primary industry is Pharmaceuticals.
-
Is Shinpoong Pharmaceutical a private or public company?
Shinpoong Pharmaceutical is a Public company.
-
What is Shinpoong Pharmaceutical’s stock symbol?
The ticker symbol for Shinpoong Pharmaceutical is 019170.
-
What is the current stock price of Shinpoong Pharmaceutical?
As of 13-Nov-2026 the stock price of Shinpoong Pharmaceutical is $5.94.
-
What is the current market cap of Shinpoong Pharmaceutical?
The current market capitalization of Shinpoong Pharmaceutical is $326M.
-
What is Shinpoong Pharmaceutical’s current revenue?
The trailing twelve month revenue for Shinpoong Pharmaceutical is $165M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
